Clinical Trial Update: Immunological Variables Associated to ICI Toxicity in Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating immunological variables associated with immune checkpoint inhibitor toxicity in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Head and Neck Cancer
• Hepatocellular Carcinoma
• Malignant Mesothelioma
• Melanoma
• Merkel Cell Carcinoma
• Msi-h Colorectal Cancer
• Non-melanoma Skin Cancer
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer

Snippet

Sponsor: Jules Bordet Institute | Conditions: Breast Cancer, Melanoma | Phase 2 | Status: UNKNOWN